Status:
COMPLETED
Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)
Lead Sponsor:
Pfizer
Conditions:
Arthritis
Rheumatoid
Eligibility:
All Genders
16+ years
Brief Summary
This survey is conducted to investigate safety and efficacy under the post marketed drug utilization on the patient with rheumatoid arthritis (only for patients with an inadequate response to prior co...
Detailed Description
Implemented as a Special Investigation by Central Registration System
Eligibility Criteria
Inclusion
- Patients need to be administered etanercept in order to be enrolled in the survey
- Patients who have changed regimen from 10 mg twice a week administration to 25 mg once a week administration.
Exclusion
- Patients who have been administered etanercept 50mg once a week
- Patients who have been administered etanercept 25mg once a week
Key Trial Info
Start Date :
May 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT01230177
Start Date
May 1 2011
End Date
April 1 2013
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taihaku Sakura Hospital
Sendai, Miyagi, Japan, 982-0032